Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biosecurity

    Emergent BioSolutions Awarded 19.7M Ebola Antibody Contract

    By Global Biodefense StaffJuly 20, 2015
    Ebola Monoclonal Antibody Countermeasures
    Share
    Facebook LinkedIn Reddit Email

    Emergent BioSolutions today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) valued at $19.7 million to develop and manufacture Ebola monoclonal antibodies.

    This contract is the first BARDA Task Order for an Ebola countermeasure awarded to Emergent under the Center for Innovation in Advanced Development and Manufacturing (CIADM) program.

    Under the scope of this two-year contract, Emergent will manufacture cGMP lots of three Ebola monoclonal antibodies in CHO cell lines at a 2000 Liter scale. The company will conduct process development, analytical method development, execute small-scale production runs, and perform cGMP cell banking leading to cGMP manufacture of bulk drug substance.

    “Emergent is pleased to work with BARDA on this contract, which reflects the government’s commitment to enhancing public-private partnerships and, together, taking steps to achieve a state of readiness against emerging public health threats,” said Adam Havey, executive vice president and president, biodefense division of Emergent BioSolutions.

    The monoclonal antibodies will be manufactured at Emergent’s Bayview Campus in Baltimore, which is equipped with disposable manufacturing technology such as single use bioreactors that enable production of viral and non-viral products with a quick turnaround.

    In 2012, the facility designated by the U.S. Department of Health and Human Services as a CIADM, which allows the company to contract with the U.S. government through task order requests for requirements such as operational readiness, development and manufacturing of CBRN products, warm base maintenance, surge manufacturing, and workforce development.

    In this facility, Emergent has successfully manufactured product candidates for the company’s pipeline and for ongoing collaborations, including most recently the MVA-EBOZ Ebola vaccine candidate, which is now being evaluated in a Phase 1 clinical study.

    Antivirals ASPR BARDA Ebola Emerging Threats HHS
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleDevelopment of Monoclonal Antibodies to Tetrodotoxin
    Next Article DoD Seeks Tuberculosis Disinfectant

    Related Stories

    Committee to Examine Transmission and Geographic Spread of Chronic Wasting Disease

    September 24, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    The Basics on the Nipah Virus Outbreak in India

    September 19, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.